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Abstract: The tumour microenvironment (TME) is composed of extracellular matrix and non-mutated
cells supporting tumour growth and development. Tumour-associated macrophages (TAMs) are
among the most abundant immune cells in the TME and are responsible for the onset of a smouldering
inflammation. TAMs play a pivotal role in oncogenic processes as tumour proliferation, angiogenesis
and metastasis, and they provide a barrier against the cytotoxic effector function of T lymphocytes
and natural killer (NK) cells. However, TAMs are highly plastic cells that can adopt either pro-
or anti-inflammatory roles in response to environmental cues. Consequently, TAMs represent an
attractive target to recalibrate immune responses in the TME. Initial TAM-targeted strategies, such as
macrophage depletion or disruption of TAM recruitment, have shown beneficial effects in preclinical
models and clinical trials. Alternatively, reprogramming TAMs towards a proinflammatory and
tumouricidal phenotype has become an attractive strategy in immunotherapy. This work summarises
the molecular wheelwork of macrophage biology and presents an overview of molecular strategies to
repolarise TAMs in immunotherapy.
Keywords: tumour-associated macrophages; repolarisation; cancer immunotherapy; tumour
microenvironment; small molecules
1. Introduction
A tumour-promoting microenvironment plays an important role in tumour development and
hampers the onset of an effective immune response against tumour cells. The TME consists of
extracellular matrix, an expanding vasculature, stromal cells and various types of immune cells. TAMs
cover the dominant portion of these immune cells and can account for up to 30% of the tumour mass [1].
TAMs are responsible for the onset of a tumour-promoting, smouldering inflammation, which prevents
T cells and NK cells from attacking the tumour [2]. Instead, TAMs enhance tumour development
into malignancy and are generally associated with a poor prognosis [3]. This review summarises
the molecular mechanisms of macrophage polarisation and discusses recent developments in TAM
repolarisation strategies, their associated mechanisms and therapeutic efficacy. An overview of ‘M2 to
M1′ macrophage reprogramming molecules is presented in Table 1.
2. Macrophages in Tumourigenesis
Macrophages are immune cells derived from the myeloid lineage and play an important role in
tissue development, homeostasis and immune surveillance [4]. Mirroring the paradigm of Th1/Th2
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lymphocytes, macrophages can be subdivided into two polarised subsets; classically activated
macrophages and alternatively activated macrophages, M1 and M2, respectively. Macrophages
polarise along the type 1 pathway in response to Th1-derived cytokines as interferon gamma (IFNγ),
colony stimulating factor 2 (CSF2 or GM-CSF) or toll-like receptor (TLR) agonism [5,6]. This induces
expression of major histocompatibility complex II (MHC II) and costimulatory molecules (CD80 and
CD86) leading to efficient T cell priming. M1 cells produce nitric oxide (NO) and reactive oxygen
species (ROS) associated with microbicidal and tumouricidal activity. Furthermore, M1 polarised
macrophages recruit new Th1 cells via chemokines CXCL9 and CXCL10 and produce proinflammatory
cytokines as tumour necrosis factor alpha (TNFα) and interleukins (IL)-1β, IL6, IL12, and IL23 [7,8].
M1 infiltration in tumours is associated with a good prognosis in some cancers [9,10]. On the other
end of the spectrum are M2 macrophages. This immunosuppressive state is initiated by Th2-derived
cytokines such as IL4, IL10, IL13, transforming growth factor beta (TGFβ), prostaglandin E2 (PGE2) or
colony stimulating factor 1 (CSF1 or M-CSF) [10,11]. M2 macrophages lose their antigen presenting
capabilities and are involved in tissue remodelling, debris scavenging and immune modulation [4].
They support angiogenesis by secretion of adrenomedullin and vascular epithelial growth factors
(VEGFs), and express immunosuppressive molecules such as IL10, programmed death ligand 1 (PD-L1)
and transforming growth factor beta (TGFβ) [12,13].
This simplified M1/M2 definition provides a useful framework to classify macrophage function
in macrophage biology. However, this definition overlooks the spectrum of trophic/developmental
macrophages involved in tissue repair, angiogenesis or bone remodelling that can be found in normal
physiology [12,14,15]. During tumour development at least six distinct TAM populations can be found,
often sharing features of both types, M1 and M2 [2,6,16]. This spectrum of activation states is controlled
by the cytokine profile of the TME, where different cytokines can integrate and induce a broad and
dynamic range of functions (Figure 1). Qian and Pollard reasoned that these distinctive phenotypes
represent individual stages of tumour development; starting from tumour proliferation and invasion
towards more malignant processes as vascularisation and metastasis [2].
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Figure  1.  Schematic  representation  of  the  functions  of M1  and M2‐like macrophages  in  tumour 
development. During early stages of tumourigenesis activated (M1) macrophages present antigens 
and support cytotoxic T lymphocytes (CTL) by the production of proinflammatory cytokines. They 
eliminate  tumour  cells with nitrogen  and  oxygen  radicals  or  by phagocytosis. These  antitumour 
macrophages  can  be  seized  by  the  tumour  and  shifted  to  an  M2‐like  state  by  secretion  of 
immunosuppressive cytokines. The formed M2‐like macrophages suppress CTL function and redirect 
Figure 1. Schematic rep sentation of the fu s of M1 and M2-like macrophages in tumour
developm nt. During early stages of tumourige sis ctivated (M1) macrophages present antigens
and support cytotoxic T lymphocytes (CTL) by the production of proinflammatory cytokines. They
eliminate tumour cells with nitrogen and oxygen radicals or by phagocytosis. These antitumour
macrophages can be seized by the tumour and shifted to an M2-like state by secretion of
immunosuppressive cytokines. The formed M2-like macrophages suppress CTL function and redirect
them to immunosuppressive T cell subsets. M2 polarised TAMs support tumour growth in all stages of
disease including proliferation, angiogenesis and metastasis.
Molecules 2019, 24, 9 3 of 25
The onset of tumourigenesis is often accompanied by a non-resolving inflammation. Central
in this process are tissue-resident macrophages (F4/80hi), such as Kupffer cells, Langerhans cells,
microglia etc., that co-evolve with the tumour [1,2]. They provide a mutagenic environment by
producing nitrogen or oxygen radicals and secrete a variety of growth factors [17–19]. Following
the development of an intraepithelial lesion, this macrophage phenotype is shifted towards an
immunosuppressive subset by tumour-derived cytokines as IL4, IL10 and IL13. Bone marrow-derived
monocytes (F4/80low) are recruited to the tumour via secretion of CSF1 and monocyte chemoattractant
protein 1 (MCP1 or CCL2). These monocytes differentiate into M2 polarised macrophages under
influence of CSF1, IL4 and IL13 [1,3,19]. The tumour-educated M2-like macrophages resemble
trophic/developmental macrophages, downregulate tumouricidal activity and inhibit cytotoxic T cells
(CTLs) via IL10 secretion [20]. Instead, they support immunosuppressive, regulatory T cells (Tregs)
leading to immune evasion and proliferation of the tumour. M2 polarised TAMs promote an invasive
phenotype by supplying promigratory factors as epidermal growth factor (EGF) and they upregulate
and secrete cysteine cathepsins in response to IL4 [21,22]. Cysteine cathepsins degrade the extracellular
matrix providing a path for invading tumour cells and cleave adherens junction proteins such as
E-cadherin [21,23]. Tumour invasion proceeds in lock-step with macrophages, where macrophages
lead the migratory front [24–27]. This macrophage-mediated motility centres around two paracrine
signalling loops, comprised of TAM-expressed EGF and tumour-derived CSF1 [28,29]. Interestingly,
inhibition of either the EGF or CSF1 signalling pathways results in a constrained lesion in mouse
models [26,28].
Tumour expansion is followed by neovascularisation, the key step in the benign-to-malignant
transition [2]. Without this ‘angiogenic switch’ the tumour lesion remains severely restricted (2–3 mm3)
and does not metastasise [10]. In response to the increased hypoxia, TAMs secrete angiogenic factors
such as adrenomedullin, VEGF-A and VEGF-C, and produce proangiogenic cytokines as TNFα, IL1β
and urokinase-type plasminogen activator (uPA). Moreover, TAM-derived cathepsins and matrix
metalloproteases (MMPs) facilitate angiogenesis by releasing growth factors from the ECM and
by cleaving ECM components facilitating recruitment of endothelial cells [30–32]. Apart from these
wound-healing M2 macrophages, there is a specialised subset exclusively involved in neo-angiogenesis,
TIE2-expressing macrophages. These TIE2-expressing cells are not recruited with CCL2, but via other
tumour-derived chemokines as TIE2-ligand angiopoietin 2, CCL3, CCL5 and CCL8 [32]. These
specialised cells are regarded as the major culprit in tumour vascularisation and elimination of this cell
type in vivo severely limits the angiogenic switch [16,33].
The last stage in tumourigenesis is dissemination from the primary site. This process is highly
inefficient as most circulating malignant cells are cleared by the immune system [34]. TAM-derived
proteases support intravasation by degrading the epithelial basement membrane and cleave cell
adhesion proteins [15,23]. Following the invasion of blood or lymphatic vasculature, a specialised
TAM subset primes the metastatic site by deposition of fibronectin and release of VEGFs and
angiopoietins [35]. Furthermore, this pre-metastatic niche provides a platform of chemokines (IL1, IL6
and TNFα), growth factors and adhesion molecules, enabling circulating tumour cells to engraft the
secondary site [36].
3. Targeting Tumour-Associated Macrophages in the Tumour Microenvironment
The vast majority of TAMs promote tumourigenesis and correspondingly specific depletion of
macrophages has shown promising results with in vivo models [37]. Especially macrophage-targeted
delivery of liposomal clodronic acid (dichloromethylene diphosphonate) has been extensively
researched in preclinical models [2,36,38,39]. Positive effects include severely restricted angiogenesis,
disrupted metastasis and a reduced tumour growth.
Tumour infiltration of TAMs is primarily mediated by CSF1, and genetic ablation of CSF1 in
mouse models severely limits tumour progression in comparison with wild type mice [40,41]. Transient
disruption of the CSF1-pathway with antibody treatment or antisense oligonucleotides generates
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a potent antitumour response in preclinical models [42,43]. Moreover, CSF1 is an important regulator
of TAM polarisation into an M2 phenotype [11]. The other key mediator in macrophage recruitment is
CCL2 (MCP1) and disruption of this cytokine severely limits vascularisation and metastasis in animal
models [44,45]. Several clinical trials targeting the CSF1 and CCL2 axes have recently been reviewed
by Quail and Joyce [1].
The aforementioned strategies focus on the depletion of macrophages from the TME, however,
this overlooks the beneficial effects of M1 polarised TAMs. For instance, M1 infiltration is associated
with a good prognosis in non-small cell lung cancer (NSCLC) [10]. The tumour-promoting
functions of TAM subsets is primarily supported through cytokine crosstalk with the oncogenic
microenvironment [3]. Through hijacking this macrophage polarisation and shifting the balance
towards an M1-like phenotype in situ, an antitumour immune response can be provoked.
This re-education of TAMs has been coined about a decade ago with genetic disruption of nuclear factor
kappa beta (NFκB) signalling to shift macrophage polarisation to an M1-like state [46]. The skewed
M1 subset was characterised by an increase in iNOS and IL12, and a decreased IL10 and arginase 1
(ARG1) expression. The obtained immunogenic TAMs induced a strong NK cell infiltration in vivo
and a sustained tumouricidal effect was observed [46]. Over the last years several small molecules and
nanoparticle formulations have been reported to skew macrophage polarisation towards an M1-like
state. An overview of these molecules will be presented in the following paragraphs, clustered by
molecule type and mechanism of action.
3.1. TLR Agonists
The most straightforward method of inducing M1 polarisation is through stimulation with TLR
ligands. This activates gene regulators such as NFκβ P50-P65 and signal transducer and activator of
transcription 1 (STAT1) (Figure 2). Additionally, TLR4 agonists stimulate activator protein 1 (AP-1) and
interferon regulatory factor (IRF) 3 signalling, which leads to a broad activation of M1-associated genes.
For example, Yang et al. described that TLR4 engagement by Pseudomonas aeruginosa
mannose-sensitive hemagglutinin (PA-MSHA) potently repolarised CD163+ TAMs into an M1-like
phenotype in vitro, characterised by an increase in TNFα and iNOS expression and a decrease in
IL10 and ARG1 [47]. Wang and co-workers found that PA-MSHA re-educated TAMs in a xenograft
mouse model of gastric carcinoma. PA-MSHA treatment significantly increased NFκβ signalling,
which upregulated IL12 and TNFα expression. Moreover, they found an increase in IFNγ suggesting
profound Th1 cell infiltration. This treatment inhibited the proliferation and invasion of gastric
cancer cells in vitro and demonstrated tumour growth inhibition in vivo [48]. Similarly, Liu and Duan
reported that PA-MSHA increased M1 cell infiltration in a mouse model of bladder cancer and inhibited
tumour growth [49]. Combination of PA-MSHA with EGF receptor antagonist gefitinib demonstrated
a synergistic effect in a xenograft mouse model of NSCLC. Interestingly, PA-MSHA treatment could
even resensitise gefitinib-resistant cells both in vitro and in vivo [50]. PA-MSHA is currently in clinical
use for treatment of malignant pleural effusion (MPE) in advanced lung cancer patients [47].
Likewise, TLR4 agonism by heat-treated Mycobacterium indicus pranii (Mw) was investigated
in combination with DTA-1, an agonistic antibody for glucocorticoid-induced TNFR-related protein
(GITR). GITR acts as a costimulatory molecule in cytotoxic T cell activation, stimulates IFNγ and IL2
production and suppresses immunosuppressive Treg expansion. Combination of Mw and DTA-1
potently repolarised TAMs in a mouse model of advanced stage melanoma. TAM repolarisation into
an M1-like state was confirmed by a significant increase in IL12, iNOS and MHC II, and a decrease in
IL10 and TGFβ. DTA-1/Mw combination therapy generated an efficient host immune response and
led to almost complete regression of advanced stage solid tumours in mouse models [51].
TLR4 activation has also been investigated with cationic polymers. The positively charged
polyethyleneimine (PEI) and cationic dextran (C-dextran) polymers were able to reprogram TAMs
towards an M1 phenotype. Reprogramming was associated with an increased IL12, iNOS and MHC II
expression and a decreased IL10, ARG1, VEGF and MMP9 expression. Treatment with PEI/C-dextran
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particles also demonstrated profound CD8+ T cell and NK cell infiltration and inhibited cancer growth
in an allograft sarcoma model [52].
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Figure 2. Schematic representation of the key signalling pathways driving macrophage polarisation.
M1 stimuli as IFNγ, bacterial lipoproteins or lipopolysaccharides induce IRF3, IRF5, IRF7, STAT1 and
P50-P65 NFκβ signalling leading to a proinflammatory response. In contrast, M2 stimuli as IL4, IL10
and IL13 activate IRF4, STAT3, STAT6 and P50-P50 NFκβ signalling resulting in anti-inflammatory
gene expression and tumour progression. The crosstalk between these regulatory pathways determines
the exact outcome of macrophage activity.
Vidyarthi et al. recently reported that TLR3 ligand poly I:C reprogrammed macrophages in
a mouse model of colon cancer. They observed an increased production of IL6, IL12, TNFα, iNOS,
an enhanced antigen uptake and an improved T cell priming. Furthermore, they showed that poly I:C
could compete with IL4 and IL13 priming, effectively preventing M2 polarisation. Lastly, they showed
that poly I:C reverted M2 TAMs to an M1-like phenotype in a IFNα/β-dependent manner and poly
I:C potently inhibited tumour growth in vivo [53].
TLR7 activation is another attractive target for TAM repolarisation as it activates both NFκβ-
and IRF7-signalling in macrophages. IRF7 stimulates IFNα production, which leads to a type 1
interferon response. Let-7b is a synthetic miRNA mimic (5′-UGAGGUAGUAGGUUGUGUGGUU-3′)
that engages TLR7 and redirects TAMs to an inflammatory phenotype. Furthermore, Let-7b directly
suppresses IL10 production in CD4+ T cells preventing 2 polarisation [54]. annose receptor, C type
1 (MRC1 or CD206)-targeted nanoparticles, loa e ith et-7b, isplaye potent T repolarisation
in vivo, characterised by an increased expression of CD86, MHC II, IL12 and iNOS and a decrease in
ARG1 and IL10. Furthermore, L t-7b nanoparticles induced massive infiltration of CD8+ T cells and
reduced primary tumour v lume by up to 70% in a mouse model f breast c ncer [55].
Resiquimod (R84 ) is a ynthetic TLR7/8 agonist a d w s recently reported to po ntly re-educate
TAMs [56]. Rodell and co-workers performed a morpho etric ini-screen of propo ed reprogramming
molecules and noted that especially TLR7 and TLR8 engagement showed pot re-educati n of
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macrophages in vitro. Next, they developed a R848-encapsulated TAM-targeted nanoparticle by
crosslinking β-cyclodextrin. These nanoparticles effectively accumulated in TAMs in the tumour
microenvironment, repolarised them towards an inflammatory phenotype and showed profound
tumouricidal effects in a MC38 mouse model of colon cancer. No systemic adverse effects were noted,
whereas non-targeted TLR7 or TLR8 agonists have previously shown dose-limiting adverse effects
in clinical studies [57,58]. Lastly, it was shown that combination of the R848-nanoparticles with an
anti-PD1 checkpoint inhibitor synergised to give improved immunotherapy response and complete
rejection of tumours in two out of seven mice. Moreover, mice cured in the course of treatment
resisted secondary tumour challenge, indicating that an effective anti-tumour memory had been
established [56].
Motolimod is a potent and selective small molecule agonist of TLR8 and is in clinical trials for
the treatment of multiple cancers. Motolimod shows potent immune activation even in late-stage
cancer patients [59]. In a phase I clinical study it was found that combination of motolimod with
EGFR inhibitor cetuximab could potently re-educate TAMs in squamous cell carcinoma patients.
Repolarisation was characterised by an increase in IL6, MIP-1β, and MCP1 secretion and an increase in
NK cell circulation and activation. Two out of eleven patients displayed partial response and five out
of eleven patients showed disease stabilisation. Motolimod is currently under further investigation as
adjuvant therapy in a phase II trial as therapy for squamous cell carcinoma [60].
TLR9 activation with synthetic unmethylated cytosine-guanine oligodeoxynucleotides
(CpG-ODN) leads to activation of interleukin 1 receptor-associated kinase 1 (IRAK)/TNF receptor
associated factor (TRAF)-pathway which in turn activates NFκβ and AP-1 signalling [61]. Chen
et al. demonstrated that self-assembled CpG-ODN gold nanoparticles could potently stimulate
macrophages in vitro and in preclinical models in a TLR9-dependent manner [62]. Guiducci et al.
reported that combination of CpG-ODN with an anti-IL10 receptor (anti-IL10R) antibody promptly
switched M2 cells to an M1 phenotype and this immunotherapy synergised with adenoviral delivery
of CCL16-encoding DNA that increases immune cell infiltration. This three-pronged immunotherapy
resulted in remarkable rejection of large tumours in three different allograft mouse models (TSA and
4T1 breast cancers and MC38 colon cancer). The authors described massive haemorrhagic necrosis
initiated by activated M1 macrophages and subsequent dendritic cell (DC) and CTL activation leading
to almost complete tumour rejection in all three mouse models [63]. Similarly, CpG-ODN was also
investigated in combination with an agonistic CD40 antibody in established tumours of B16 melanoma
and 9464D neuroblastoma mouse models. The combined immunotherapy potently induced M1
markers (CD40, CD80, CD86, MHC II, TNFα and IL12) in vivo and synergised with chemotherapeutic
regimens potently inhibiting tumour growth in melanoma and neuroblastoma mouse models [64].
Lastly, Song et al. investigated manganese dioxide nanoparticles (MnO2NP) modified with
mannan (Man) and hyaluronic acid (HA) to alleviate tumour hypoxia and reprogram M2 TAMs in
a preclinical study. Mannan is a ligand for MRC1 and can be exploited to target M2 macrophages.
HA is an important component of the extracellular matrix and low molecular weight HA has been
reported to promote M1 polarisation [65]. The HA-coated nanoparticles successfully repolarised TAMs
in vivo, which was suggested to be dependent on TLR2 or TLR4 signalling. Finally, combination of
Man-HA-MnO2NP with chemotherapy significantly inhibited tumour growth and invasion in a mouse
model of breast cancer [66].
Altogether, this shows that TLR-mediated TAM repolarisation is a potent antitumour strategy.
To date, a limited number of small molecule TLR agonists have been investigated for TAM
reprogramming capacity. Several alternative (small molecule) TLR ligands have been synthesised
which deserve attention in this context. A few examples have been depicted in Figure 3. [67–70].
Furthermore, combination of TLR ligands into multivalent conjugates could lead to synergistic effects
and phenotypically distinct polarisation states [71,72].
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pyrimidine (4‐IPP) an inhibitor of macrophage migration inhibitory factor (MIF). MIF is thought to 
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combination therapy increased the tumouricidal activity of repolarised TAMs in a xenograft mouse 
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3.2. Cytokines
A second way of stimulating M1 polarisation is by directly administering proinflammatory
cytokines. Similar to TLR agonists, treatment with cytokines is associated with systemic adverse
effects [74]. In order to avoid these side effects, intra-tumoural injection or targeted delivery systems
have been adopted to selectively target the tumour lesion.
CSF2 is a cytokine that regulates macrophage function by enhancing antigen presentation and
immune responsiveness. Engagement of the CSF2 receptor is involved in regulating JAK2/STAT3/5,
MAPK, NFκB, and PI3K signalling. Eubank et al. demonstrated that intra-tumoural injection of
CSF2 increased the number of TAMs in a mouse model of breast cancer and triggered the ability
of TAMs to produce soluble VEGF receptor 1 (sVEGFR1) [75]. sVEGFR1 secretion by macrophages
blocks angiogenesis by binding VEGF. Furthermore, CSF2 treatment repolarised M2-like macrophages
towards an M1 phenotype, characterised by increased iNOS expression and decreased IL4 and
IL10 production. This prevented metastasis and delayed tumour growth in a mouse model
of lung cancer [75]. In a similar preclinical study, CSF2 was investigated in combination with
4-iodo-6-phenyl-pyrimidine (4-IPP) an inhibitor of macrophage migration inhibitory factor (MIF).
MIF is thought to control M2 polarisation of TAMs in advanced multiple melanoma. Combination
treatment demonstrated improved upregulation of M1 markers and downregulation of M2 markers.
Moreover, combination therapy increased the tumouricidal activity of repolarised TAMs in a xenograft
mouse model of multiple myeloma [76].
IL12 is a cytokine produced by macrophages and DCs that promotes CTL expansion. IL12 has
been shown to activate multiple signalling pathways including JAK2/STAT4 activation. Moreover,
IL12 treatments leads to IFNγ production by T cells and NK cells. To deliver IL12 to the TME several
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approaches have been investigated. Watkins et al. reported that IL12 containing microspheres were
able to reprogram TAMs in a Lewis lung carcinoma (LLC) mouse model, which was associated
with a decrease in IL10, MCP1, MIF and TGFβ production and an increase in TNFα, IL15 and
IL18 secretion [77]. Wang and co-workers recently reported a pH-responsive nanoparticle designed
to deliver IL12 to the tumour lesion. The IL12 nanoparticles potently re-educated TAMs towards
a proinflammatory state in a xenograft mouse model of malignant melanoma and resulted in potent
immune activation at the tumour site without systemic toxicity [74].
Cardoso et al. reported on chitosan/poly (γ-glutamic acid) polyelectrolyte multilayer films
(Ch/γ-PGA PEMs) for the delivery of IFNγ to human anti-inflammatory macrophages in vitro.
Ch/γ-PGA PEMs caused slow and persistent release of IFNγ and efficiently reprogrammed
IL10-polarised macrophages towards an M1-like state, characterised by an increased IL6 production
and a decrease in IL10 secretion. Moreover, reprogrammed macrophages adopted M1-like morphology,
decreased human gastric cancer cell invasion in vitro and reduced gastric cancer cell-induced
angiogenesis in ovo [78].
Lastly, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) was also reported to
skew TAM subsets in vitro. Like other TNF superfamily members TRAIL can induce apoptosis in
tumour cells, whereas the majority of non-malignant cells are resistant. Moreover, TRAIL incudes
macrophage polarisation through Erk1/2 and NFκβ signalling. In human macrophages co-cultured
with human NSCLC cells TRAIL treatment upregulated proinflammatory cytokines such as IL1β, IL6
and TNFα and induced tumouricidal effects in vitro [79].
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Table 1. TAM reprogramming molecules.
Molecule Target Signalling Pathway Type of Study Reference Comments
TLR Agonists
Poly I:C TLR3 NFκβ In vitro and in vivo [53]
Cationic polymers PEI/ C-dextran TLR4 NFκβ and IRF3 In vitro and in vivo [52]
Mycobacterium idicus pranii TLR4 NFκβ and AP-1/MAPK P38 In vivo [51] Studied in combination with DTA-1
pseudomonas aeruginosa mannose-sensitive
hemagglutinin (PA-MSHA) TLR4 NFκβ and IRF3 In vitro and in vivo [47–50] Approved for advanced lung cancer
Let-7b microRNA mimic TLR7 and anti-IL10 NFκβ and IRF7 In vivo [55] Administered in a MRC1-targeted nanoparticle
Resiquimod (R848) TLR7/8 NFκβ and IRF7 In vitro and In vivo [56] Administered in a β-cyclodextrin nanoparticle
Motolimod TLR8 NFκβ In vivo and phase I/II clinical trials [59,60,80]
CpG motifs TLR9 NFκβ and AP-1 In vivo [62–64]
Hyaluronic acid TLR-2 or TLR-4 NFκB or IRF3 In vivo [66]
Cytokines
CSF2 CSF2 receptor JAK/STAT3/5, MAPK, NFκβ, and PI3K In vivo [75,76] Studied in combination with 4-IPP
IL12 IL12 receptor JAK2/STAT4 In vivo [74,77] Administered in a poly(β-amino ester) nanoparticle
IFNγ IFNγ receptor STAT1 In vitro [78] Administered as a chitosan/poly(γ-glutamic acid) nanoparticle
TRAIL TRAIL receptor 1 NFκβ and ERK1/2 In vitro [79]
Antibodies
Anti-CSF1 CSF1 NFκβ, ERK1/2 and miR21 In vivo [81]
Anti-LILRB2 LILRB2 receptor NFκβ, Erk1/2 and Blocks Akt/STAT6 In vitro and in vivo [82]
Anti-MARCO MARCO FcγRIIB In vivo [83]
Anti-CD40 CD40 NFκβ, ERK1/2 and P38 MAPK In vivo [64] Studied in combination with CpG-ODN
Anti-IL10 receptor IL10Rα Blocks Akt/STAT3 in vivo [63] Studied in combination with CpG-ODN and CCL16
Anti-phosphatidylserine Phosphatidylserine FcγRII/III In vivo and phase I/II/III clinical trials [84–87]
Anti-TREM-1 TREM-1 TREM-1/DAP12/Syk In vitro [88]
Anti-VEGFR-2 VEGF receptor 2 Decreased hypoxia sensing In vivo [89]
Bispecific anti-angiopoietin-2 anti-VEGF-A antibody Angiopoietin-2 and VEGF-A Decreased hypoxia sensing In vivo [90]
RNAs
miR155/miR125b2 TNFα/SOCS1/IRF4 Enhances TNFα translation and blocksSOCS1 and IRF4 In vitro [91,92] Administered in a hyaluronic acid-based nanoparticle
IκBα siRNA IκBα NFκβ In vitro [93] Administered in a mannosylated nanoparticle
MyD88/TNF mRNA in S. cerevisae MYD88/TNF receptor NFκβ and AP-1 In vitro [94] Empty S. cerevisae also activates macrophages
Small Molecules
NS-398 COX2 inhibitor Blocks PI3K/Akt In vivo [95]
Etodolac COX2 inhibitor Blocks PI3K/Akt In vivo [96]
Celecoxib COX2 inhibitor Blocks PI3K/Akt In vivo [97]
DMXAA STING-agonist TBK1/NFκβ In vivo [98]
2‘3‘-cGAMP STING-agonist TBK1/NFκβ In vitro [98]
Pexidartinib CSF1R-inhibitor STAT3, IRF4 In vivo [99,100]
BLZ945 CSF1R-inhibitor STAT3, IRF4 In vivo [101]
Ibrutinib BTK inhibitor Blocks BTK In vitro [102] Approved for leukemia
TG100-115 PI3Kγ inhibitor Blocks PI3Kγ In vitro [102]
HS-1793 HIF1 antagonist JAK/STAT1 In vitro [103,104]
Vorinostat HDAC inhibitor HDAC2 In vivo [105–107] Administered in a redox-responsive nanoparticle
Sorafenib Tyrosine kinase inhibitor Blocks Akt/STAT6 In vivo [108–110] Approved for advanced kidney cancer
Sunitinib Tyrosine kinase inhibitor Blocks STAT3 In vivo [111] Studied in combination with anti-GITR, approved for renal andGI cancers
Baicalin Unknown RelB/P52 In vivo [112]
Chlorogenic acid Unknown Activates STAT1 and blocks STAT6 in vivo [113]
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Table 1. Cont.
Molecule Target Signalling Pathway Type of Study Reference Comments
Emodin Unknown Blocks Akt/STAT6 In vivo [114,115]
Hydrazinocurcumin Unknown Blocks STAT3 In vivo [116]
CDDO-Me Unknown Unknown In vivo [117]
Dopamine Dopamine receptor 2 Unknown In vivo [118]
CuNG ROS generation MAPK P38, ERK1/2, NFκβ and AP-1 In vivo [119,120]
Zoledronic acid Unknown NFκβ In vivo [121–123] Approved for osteoporosis and bone metastases
Metformin Unknown AMPK/NFκβ In vivo [124–126]
Chloroquine Unknown NFκβ, P38 MAPK and TFEB In vivo [127,128]
Others
Histidine-rich glycoprotein PIGF Unknown In vivo [129]
β-Glucan Dectin-1 Erk1/2 In vivo [130]
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3.3. Antibodies
An alternative approach to skew TAM polarisation is to impede anti-inflammatory signalling.
Antagonistic antibodies can directly shutdown a specific M2-related pathway, which in turn allows
macrophages to adopt a proinflammatory phenotype. For example, Zhu et al. reported on the TAM
repolarising effect of an anti-CSF1 antibody in preclinical models. CSF1 blockade decreased M2 tumour
infiltration in vivo and reprogrammed resident TAMs to an inflammatory phenotype. This anti-CSF1
treatment sensitised resistant pancreatic ductal adenocarcinoma (PDAC) towards treatment with
checkpoint inhibitors (anti-PD1 or anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA4)).
The combined immunotherapy led to potent reduction of tumour progression in mouse melanoma
and PDAC models, and complete regression of well-established primary tumours in 80% of cases [81].
Likewise, combination of an anti-MARCO with an anti-CTLA4 antibody was investigated in
mouse model of melanoma. MARCO is a pattern recognition receptor for low-density lipoproteins
and is associated with M2 polarisation of macrophages. Anti-MARCO treatment potently repolarised
TAMs in an FcγRIIb-dependent manner and in combination with anti-CTLA4 immunotherapy showed
enhanced anti-tumour effects in mouse models of melanoma and colon carcinoma [83].
Chen and co-workers recently reported on an antagonistic antibody for leukocyte
immunoglobulin-like receptor B (LILRB). LILRB family members are negative regulators of myeloid cell
activation and correspondingly LILRB blockade increased Erk1/2 and NFκβ signalling and reduced
activation of Akt/STAT6 signalling cascades, indicating a shift toward M1 polarised macrophages.
Moreover, anti-LILRB2 prevented M2 polarisation by CSF1 or IL4 treatment. Lastly, LILRB2 antagonism
potently enhanced the efficacy of anti-PD1 treatment in a mouse model for NSCLC [82].
Phosphatidylserine (PS) is a phospholipid that inhibits inflammatory responses. In healthy
tissues, PS resides in the plasma membrane and is exposed only upon apoptosis. During apoptosis,
PS receptors (PSR) on macrophages and DCs bind exposed PS on dying cells, which promotes
tolerance by triggering IL10 and TGFβ expression. Endothelial cells in the tumour vasculature and
tumor-derived microvesicles constitutively expose PS, hereby suppressing immune cell function [131].
Correspondingly, a PS-binding antibody, 2aG4, re-educated M2 macrophages and increased DC cell
maturation. This resulted in profound destruction of tumour vasculature and reduction in tumour
size in vivo. Combination of anti-PS with docetaxel synergised to reject established PC3 and LNCaP
prostate cancers in mice [84]. Similarly, Cheng and co-workers reported on a combination therapy of
2aG4 with tyrosine kinase inhibitor sorafenib in a mouse model of hepatocellular carcinoma (HCC) and
performed a small phase I clinical trial. They found that combination therapy synergised to increase the
number of apoptotic vessels and displayed stronger tumour growth inhibition as compared to single
agent therapy in mouse models. Next, they reported that combination treatment with a humanised,
monoclonal PS antibody, bavituximab, was well tolerated in HCC patients. A phase II clinical trial
with bavituximab in HCC is currently ongoing [86]. Chalasani et al. reported on bavituximab as
adjuvant therapy to paclitaxel in a phase I clinical trial for HER2-negative breast cancer. Treatment
was well-tolerated and resulted in an overall response of 85% [85]. Lastly, bavituximab has been
investigated in a phase III clinical trial in advanced stage lung cancer. Sadly, the combination of
bavituximab with docetaxel was not superior to docetaxel alone in patients previously treated NSCLC
and the addition of bavituximab did not significantly change systemic adverse effects. However,
in patients treated with immune checkpoint inhibitors post-study, the bavituximab-treated cohorts
displayed an increased overall survival as compared to placebo-treated patients. As the authors
mentioned, this would require further investigation, though, one could hypothesise a contribution
from TAM repolarisation [87].
The hypoxic milieu of the TME is also an important driver of M2 polarisation. Hypoxia leads to
the activation of hypoxia-inducible factors (HIFs), which increases the expression of M2 associated
proteins as ARG1, VEGF, MMP7, MMP9 and COX2 [5]. Hypoxia also increases the expression
of triggering receptor expressed on myeloid cells 1 (TREM1) on both M1 and M2 macrophages.
TREM1 is a member of the immunoglobulin-like receptor family and has a critical role in acute
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inflammation. Activation of TREM1 induces iNOS, IL1β, IL6 and TNFα expression and hence
drives M1 polarisation [132]. Accordingly, Raggi and co-workers demonstrated that an agonistic
TREM1 antibody was able to reverse hypoxia-induced M2 polarisation towards an inflammatory
phenotype in vitro. This reprogramming was illustrated by an increase in IL6, IL12 and TNFα [88].
Huang et al. sought to alleviate the hypoxic environment by employing an anti-VEGFR2 antibody
(DC101). They reported that low-dose, not high-dose, anti-VEGFR2 treatment leads to improved vessel
perfusion and subsequent repolarisation of TAMs towards an M1 phenotype, characterised by an
increase in iNOS, IL12, CXCL9 expression. Furthermore, combination of vessel-normalising doses
of anti-VEGFR2 treatment synergised with cancer vaccination in the treatment of orthotopic breast
cancer in mouse models [89]. Similarly, a bispecific, antagonistic antibody (A2V) directed against
VEGF and angiopoietin-2 (Ang2) demonstrated M2 repolarisation in vivo. A2V treatment reduced
MRC1 expression and increased CXCL9 production in TAMs, though a more detailed analysis of
TAM polarisation was not reported. The bispecific antibody, A2V, was able to enhance vessel pruning,
reduce tumour burden and prolong survival in Gl261 and MGG8 glioblastoma models [90].
3.4. RNAs
A second method of inhibiting M2-related signalling pathways is by employing antisense
microRNAs (miRNAs). miRNAs are small noncoding RNA fragments that play an important
role in posttranscriptional gene suppression. For instance, miRNA-155 and miRNA-125b are
important regulators of macrophage polarisation and present interesting therapeutic targets.
miRNA-155 is upregulated in an NFκβ-mediated manner, directly enhances TNFα translation and
suppresses anti-inflammatory pathways as suppressor of cytokine signalling 1 (SOCS1) and inositol
polyphosphate-5-phosphatase (INPP5D) signalling [133]. Likewise, miRNA-125b is also enriched in
M1 polarised macrophages and suppresses IRF4, a negative regulator of IRF5 signalling [91]. miRNAs
are also important in cell-cell signalling and can be transported via exosomal vesicles. Su et al.
reported on transfection of human PDAC cells with miRNA-125b and miRNA-155 HA-nanoparticles.
The transfected tumour cells upregulated miRNA-125b and miRNA-155 expression in exosomes and
repolarised mouse M2 macrophages in a transwell co-culture assay. Parayath and co-workers recently
showed that transfection of peritoneal macrophages with miRNA-125b-containing HA-nanoparticles
repolarised macrophages in a spontaneous NSCLC mouse model, illustrated by a 300-fold increase
of iNOS/ARG1 ratio [92]. Similarly, Ortega et al. reported on the development of a MRC1-targeted
nanoparticle for the delivery of siRNA against nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor alpha (IκBα). IκBα is a suppressor of NFκβ activation and accordingly
IκBα-knockdown showed an increase in TNFα and CXCl9 and a decrease in IL10 and MRC1 secretion,
effectively re-educating macrophages into an M1-like state in vitro [93].
Alternatively, Seif and co-workers looked at the delivery of MyD88- and TNFα-encoding mRNA
to induce M1 polarisation. They employed opsonised recombinant Saccharomyces cerevisiae as a novel
delivery vehicle. This empty vehicle alone induced TLR-engagement as illustrated by the repolarisation
of M2 macrophages in vitro. The encapsulation of MyD88 and TNFα RNAs prolonged this activation
and successfully reprogrammed M2 macrophages to an antitumour M1 phenotype [94].
3.5. Small Molecules
Over recent years, several small molecules have been identified that demonstrate effects on
TAM polarisation, such as cyclooxygenase 2 (COX2) inhibitors, tyrosine kinase inhibitors (TKIs),
histone deacetylase (HDAC) inhibitors and stimulator of interferon genes (STING) agonists (Figure 4),
additional to the aforementioned small molecule TLR ligands (Section 3.1). With the identification of
these compounds several molecular mechanisms involved in TAM polarisation have been unravelled,
leading to the identification of potential therapeutic targets.
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Several COX2 inhibitors have been identified o shift macrop ages into an inflamm tory
phenotype [95–97]. COX2 inhibition disrupts prostaglandin 2 (PGE2) signalling, which in tur increases
pro- nflammatory s gnals as TNFα, IL12, and iNOS production in macro hages. Chronic inhibition of
COX2 with in ibitor NS-398 was repo ted to increase TNFα and IL12 production when ch llenged
with LPS in vivo [95]. Likewise, COX2 selectiv inhibitor etodolac induced an M1 phenotype in
a syngeneic 4T1 breast c ncer model. M1 polarisation was charact rised by an increase in MHC
II, CD80 and CD86 expression and reduced IL10, TGFβ, MMP1, MMP9, VEGF-A VEGF-C
secretion. Etodolac treatment inhibited lung metastasis formation, but did not affect primary tumour
size [96]. In a preclinical model of colorectal cancer, selective COX2-inhibitor celecoxib induced an
inflammatory M1-like phenotype, reduced metastatic behaviour and primary tumour burden [97].
Lastly, combination of celecoxib with EGFR inhibitor gefitinib was reported in a phase I clinical for
the treatment of docetaxel-resistant prostate cancer. Combination treatment was well tolerated and
inhibited tumour growth and tumour invasion in patients [134].
Downey et al. reported on two STING agonists, 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
and cyclic guanosine monophosphate–adenosine monophosphate (2′3′-cGAMP) that were able to
repolarise macrophages in mouse models for NSCLC and breast cancer. Moreover, DMXAA is a
well-known vasculature disrupting agent. Both compounds showed TAM repolarisation in vitro,
Molecules 2019, 24, 9 14 of 25
characterised by an increase in iNOS, IFNγ and IL12, and a decrease of MRC1. DMXAA-treatment
in mouse models lead to haemorrhagic necrosis in subcutaneous lung and breast tumours, but could
not show the same effects in metastatic sites. The authors reasoned that his was due the difference in
vascular structures between primary and metastatic tumours [98].
CSF1R-inhibitors have also been reported to repolarise TAMs. Though the CSF1/CSF1R axis
is primarily associated with macrophage recruitment, CSF1R engagement also plays an important
role in macrophage polarisation. Ao and co-workers found that pexidartinib did not decrease TAM
infiltration but reprogrammed TAMs in a xenograft model of hepatocellular cancer. Pexidartinib
increased CSF2 and IFNγ in the TME and displayed increased CTL infiltration [99]. Yan et al. reported
that CSF1R-inhibitor pexidartinib could potently re-educate macrophages in a mouse model for glioma
while maintaining macrophage infiltration. Repolarisation was characterised by a downregulation
of ARG1, MRC1, CD163 and IL10, though no upregulation of M1 markers was noted. Pexidartinib
potently inhibited tumour growth and combination of pexidartinib with TKI dovitinib or vatalanib
synergised to reject existing tumours in mouse models [100]. Similarly, treatment of glioblastoma
with CSF1R inhibitor BLZ945 reprogrammed TAMs to an M1-like state. BLZ945 downregulated
ARG1, MRC1 and adrenomedullin, and upregulated IL-1β expression. Lastly, CSF1R inhibition
significantly reduced established tumours and increased disease-free survival in mouse model for
glioblastoma [101].
Another way to prevent M2 polarisation is inhibition of Bruton’s tyrosine kinase (BTK). BTK plays
an important role in B cell-macrophage interactions, drives M2 polarisation and immune suppression
in PDAC. BTK signalling is dependent on phosphoinositide 3-kinase-γ (PI3Kγ). Correspondingly,
inhibition of BTK with ibrutinib or inhibition of PI3Kγ with TG100-115 skewed TAMs towards
an inflammatory phenotype as characterised by an increased expression of IL12 and a decreased
expression of TFGβ and ARG1 in vitro. Moreover, inhibition of BTK or PI3Kγ signalling suppressed
tumour growth in a mouse model for PDAC [102]. Ibrutinib is currently approved for the treatment of
mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström’s macroglobulinemia.
HS-1793, a synthetic resveratrol analogue, was reported to decrease CD206+ TAM infiltration,
downregulate TGFβ production, and upregulate IFNγ production in tumour bearing mice. TAM
reprogramming was suggested to be in an IFNγ-dependent manner [103]. Secondly, Kim et al. recently
reported that HS-1793 inhibited HIF1α activity, suppressed VEGF secretion and inhibited tumour
growth in a mouse model of breast cancer [104].
Vorinostat, a HDAC inhibitor, was recently reported as adjuvant therapy to skew macrophages
into an M1 state. Peng et al. developed a dual-targeted co-delivery system for a combination of
gefitinib and vorinostat. The trastuzumab-coated, mannosylated liposomal system efficiently targeted
both HER2-positive cancer cells and MRC1-positive TAMs, and reprogrammed protumoural, M2
polarised TAMs to an M1 phenotype, in an HDAC2-dependent manner. TAM repolarisation was
illustrated by decreased ARG1, IL10 and CD206 levels and increased iNOS, CD86, TNFα and ROS
levels. This treatment re-sensitised gefitinib resistant H1975 lung cancer and potently inhibited tumour
growth in mouse models [106]. Similarly, a combination of vorinostat and TKI sorafenib was recently
reported to increase infiltration of F4/80+ iNOS+ M1 macrophages in a mouse model for PDAC.
Combination treatment showed synergy with anti-PD1 treatment which demonstrated a further
reduction in tumour growth in comparison with anti-PD1 treatment alone. A phase I clinical trial of the
vorinostat and sorafenib combination is currently ongoing in hepatocellular carcinoma patients [107].
Sorafinib alone has also been shown to influence macrophage polarisation in vitro.
Sorafinib-treatment potentiated M0 macrophages to LPS-mediated polarisation, which was
characterised by a profound increase in IL6, IL12 and TNFα production as compared to LPS alone.
Secondly, sorafinib altered NK cell and TAM crosstalk, which lead to upregulated IFNγ expression
in NK cells and increased NK cell migratory activity in vitro [108]. Alsaab et al. recently reported
on combination of sorafenib with apoptosis inducer CFM4.16 in a hypoxia-targeted nanoparticle.
This nanoparticle delivery subsequently reprogrammed macrophages to an M1-like state in vitro, via
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inhibition of AKT1 phosphorylation preventing the activation of STAT6. Nanoparticle-treatment
potently inhibited tumour growth in a mouse model of renal cell carcinoma [109]. Similarly,
Zhang et al. recently reported on the combination of sorafinib with HDAC inhibitor panobinostat and
bromodomain protein inhibitor OTX015. This triple combination led to effective rejection of tumours in
a U87-EGFRvIII glioblastoma model and a xenograft mouse model with patient-derived glioblastoma
cells [110]. Sorafenib is currently approved for primary kidney cancer, advanced primary liver cancer,
and radioactive iodine resistant advanced thyroid carcinoma.
TKI sunitinib was reported to skew macrophages when used in combination with an agonistic
antibody against GITR. Interestingly, combination treatment potently increased MHC II, CD80, CD86,
CXCL10 and IL12 in TAMs but not with either treatment alone. The combination treatment also
increased T cell and NK infiltration, and upregulated IFNγ production in a model for metastatic renal
cell carcinoma (RCC) [111].
Tan and co-workers reported that baicalin, a natural flavonoid found in several medicinal
plants, was able to reprogram TAMs in an orthotropic mouse model of HCC. Baicalin activated
the RelB/P52 complex, a regulator of non-canonical NFκβ signalling. Activation of the RelB/P52
pathway was dependent on TRAF2 lysosomal degradation, induced by baicalin-mediated autophagy.
Baicalin-treatment of HCC mice significantly upregulated M1 markers as CD86, TNFα, and IL12, and
downregulated M2 markers IL10 and ARG1. Baicalin treatment diminished cell proliferation and
tumour motility, but could not reduce primary tumour size in HCC mice [112].
Chlorogenic acid (CHA), a phenolic compound found in coffee, apples and green tea, has been
investigated in several clinical trials and demonstrated therapeutic effects in colon, lung, brain and
breast cancers. Xue et al. studied the mechanism underlying this anti-cancer activity by looking
at CHA-mediated reprogramming of IL4 polarised M2 macrophages in vitro. CHA upregulated
expression of iNOS via STAT1 induction, while decreasing the expression of M2 markers CD206,
ARG1 and IL10 by downregulating STAT6 in M2 macrophages. CHA-treatment repolarised TAMs and
displayed partial inhibition of tumour growth in a G422 xenograft mouse model [113].
Emodin, a natural product isolated from rhubarb, suppresses STAT6 phosphorylation, which lead
to a decrease in MMP9 and survivin activity. In a mouse model of pancreatic cancer emodin-treatment
reduced primary tumour volume up to 25 percent, and decreased angiogenesis, invasion and
metastasis. [114,115].
Similarly, hydrazinocurcumin (HC), a synthetic analogue of natural compound curcumin,
reprogrammed TAMs in a STAT3-dependent manner. Zhang et al. developed a legumain-targeted
nanoparticle loaded with HC which showed potent repolarisation of TAMs in vivo, halted tumour
growth and prolonged survival in a mouse model of 4T1 breast cancer [116].
Ball and co-workers reported on a synthetic analogue of natural compound oleanolic acid,
2-Cyano-3,12-dioxo-oleana-1,9(11)-dien-28-oic acid methyl ester (CDDO-Me), that was able to help
skew macrophages to an inflammatory phenotype. Treatment with CDDO-Me before treatment with
LPS potentiated TAMs to the effects of LPS-stimulation. This co-stimulation reprogrammed TAMs
ex vivo, characterised by an increased expression of TNFα, IFNγ, CXCL9 and IL6 and decreased
expression of IL10, ARG1, VEGF and SOCS3. Furthermore, CDDO-Me-treatment of TAMS inhibited
endothelial cell tube formation in vitro [117]. Though the exact molecular mechanism underlying
this reprogramming is not fully understood, CDDO-Me has been reported to inhibit tumour growth
in several in vivo studies. For instance, CDDO-Me treatment lead to potent inhibition of tumour
growth and prevented cancer recurrence in xenograft mouse models for BxPC3 pancreatic cancer and
MiaPaCa-2-Luc PDAC [135].
Qin et al. demonstrated that dopamine repolarised TAMs and inhibited cancer development
following vascular normalisation [106]. Dopamine also directly repolarised TAMs in a
dopamine-receptor 2 (DR2) mediated manner, characterised by an increase of iNOS, CXCL9, TNFα and
IL12 and decrease in ARG1, VEGF, IL10, MRC1 and TGFβ. The exact molecular mechanism following
DR2 activation remains elusive [118].
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Copper N-(2-hydroxy acetophenone) glycinate (CuNG), a synthetic copper chelate, was reported
to reprogram M2 TAMs. Copper plays an important role in macrophage homeostasis and influences
numerous signalling pathways. For example, an increased copper concentration in macrophages
correlates with the production of inflammatory cytokines. Secondly, CuNG is a redox-active compound
and can affect ROS generation. CuNG reprogramming was characterised with elevated levels
of IL12 and IFNγ, and decreased levels of IL10 and TGFβ. Consequently, CuNG was able to
induce an anti-tumour immune response in an Ehrlich–Lettre ascites carcinoma mouse model [119].
In a follow-up study, the reprogramming capacity of CuNG was demonstrated to be dependent on
ROS generation [120].
Zoledronic acid (ZA), a third-generation bisphosphonate, is currently in clinical use to treat bone
metastasis. Coscia et al. reported that ZA also shows tumour inhibiting activity to primary tumours in
a spontaneous breast cancer model. ZA-treatment upregulated iNOS and IFNγ in the TME and showed
a decrease in IL10. TAMs macrophages were reported to have an upregulated NFκβ signalling and an
increase in iNOS production. ZA delayed tumour growth and extended survival in ErbB-2 mice [121].
Secondly, ZA has been reported to decrease CCL2 expression in early-stage breast cancer model,
preventing TAM recruitment and reducing tumour growth [122]. Lastly, Comito and co-workers
reported that ZA-treatment reduced angiogenesis, inhibited tumour invasion and prevented M2
polarisation of macrophages by decreasing IL10 levels in the TME [123]. ZA has been investigated in
a multitude of clinical trials and is currently used to treat bone metastasis and osteoporosis.
Likewise, metformin, first-line medication of type 2 diabetes, was reported to prevent M2
polarisation in several cancer models. Metformin activates AMPK1 signalling, an important kinase
in the NFκB-pathway, which suppressed IL13 induced polarisation of macrophages [124]. Moreover,
metformin-treatment lowered expression of IL4, IL10 and IL13 in tumour cells and inhibited metastasis
formation and angiogenesis in a mouse model of LLC, a xenograft model of breast and prostate cancer.
Sadly, metformin showed very limited inhibition of primary tumour growth in vivo [124–126].
Chloroquine (QC), an anti-malarial drug, was recently reported to prevent M2 macrophage
polarisation in a 4T1 breast cancer model. QC suppressed TGFβ and IL10 production in the TME and
inhibited the recruitment of Tregs and M2 macrophages. QC partially inhibited cancer growth in vivo
and prolonged survival in mice [127]. Chen and co-workers reported that QC directly reprogrammed
macrophages by stimulating lysosomal calcium release. The weakly basic QC accumulated in acidic
lysosomes, leading to an increase in cytoplasmic calcium, which activates P38/NFκβ signalling. This
induced expression of IFNγ, IL12, iNOS, CD80, CD86 and MHC II, and decreased expression of ARG1,
CD206, and IL10. Lastly, QC inhibited tumour growth of B16 melanoma and H22 hepatocarcinoma
mouse models which synergised with cyclophosphamide treatment [128].
3.6. Others
Finally, two polymeric molecules have been described to drive macrophages to an M1 phenotype.
β-glucan is a natural oligo-saccharide isolated from yeast that has been investigated for tumouricidal
activity. Liu et al. reported that β-glucan repolarises macrophages to an M1 phenotype in
a dectin-1-dependent fashion. Dectin-1 is a c-type lectin receptor for a variety of β-1,3-linked and
β-1,6-linked glucans, and dectin-1 agonism leads to NFκβ activation. Correspondingly, β-glucan
upregulated iNOS, IL1β, IL6, IL12 and TNFα and downregulated IL10 and ARG1 in a mouse model of
NSCLC. Furthermore, β-glucan reduced tumour growth and inhibited vascularisation [130].
Secondly, Rolny et al. reported on a genetic gain-of-function strategy to study histidine-rich
glycoprotein (HRG) in the TME. HRG overexpression was shown to increase IL6 and IL12 production
in macrophages as compared to HRGlow tumours. This TAM repolarisation was found to be dependent
on downregulation of placental growth factor (PGF). PGF is a member of the VEGF family and an
important regulator of vascularisation. Lastly, HRGhigh 4T1 tumours displayed vascular normalisation,
delayed growth rate and an impaired metastasis in mice. Treatment with doxorubicin was potentiated
by HRG overexpression, most likely due to the increased vessel perfusion [129].
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4. Conclusion
Myeloid cell infiltration in the TME has been designated as a key factor in the proliferation and
dissemination of cancerous growth. TAMs form the major portion of these myeloid cells and are
reported to mediate in an array of pro-oncogenic processes. In each of these processes specialised TAM
subsets can be distinguished, showing characteristics of both M1 and M2 macrophages, resembling
trophic/developmental macrophages in healthy tissues. These distinct phenotypes arise from the
highly plastic nature of macrophages and are maintained primarily via the crosstalk with the TME.
Overruling these environmental cues is the key factor in successful application of TAM-targeted
immunotherapy and requires a detailed understanding of the molecular wheelwork underlying
TAM polarisation.
In the recent years various molecules have been reported to skew TAM subsets into
an inflammatory phenotype. This has led to the identification of key cellular pathways involved
in macrophage polarisation. Robust anti-metastatic and anti-angiogenic effects are well-documented,
however, most of the described molecules lack the potency required to elicit durable tumouricidal
effects in preclinical models. The discovery and development of dedicated small molecules will be of
substantial value to overcome this challenge. For instance, recent reports have identified that small
molecule TLR ligands provide potent repolarisation of TAMs in mouse models [56,59]. Subsequent
combination of TAM reprogramming with checkpoint inhibitors (PD1 or CTLA4 antagonists) or
stimulating antibodies (CD40 or GITR agonists) displayed a remarkable synergy [51,56,64].
Secondly, TAM repolarisation showed an interesting interplay with the tumour vasculature.
On the one hand, re-educated TAMs decrease expression of angiogenic growth factors leading to vessel
normalisation. Vice versa, anti-VEGFR or anti-VEGF/anti-angiopoietin treatments decreased vascular
abnormality and reduced hypoxia, which led to repolarisation of TAMs. Vessel normalisation was
shown to sensitise the tumour to chemotherapeutic regimens (docetaxel, paclitaxel or doxorubicin)
and improved CTL and NK cell infiltration. Hence, combination of TAM reprogramming with vascular
normalisation strategies might prove an attractive strategy in cancer treatment.
A major challenge of TAM repolarisation are off-target inflammatory responses. To prevent
systemic inflammation targeting strategies can be adopted to selectively reach TAMs or the
TME. For instance, antibodies directed against upregulated antigens could be ligated to
nanoparticle-encapsulated molecules or directly conjugated to small molecule TLR ligands.
Lastly, conjugating multiple TLR ligands together could be an attractive strategy to potentiate
TAM reprogramming.
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